National Dissemination of I-Corps@NCATS: Accelerating Translation through Commercialization

I-Corps@NCATS 的全国传播：通过商业化加速翻译

• 批准号: 10415910
• 负责人: Molly Wasko
• 金额: $ 888.96万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-05-06 至 2024-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10415910
• 关键词: Academic Medical Centers; Administrative Supplement; Biomedical Research; Clinical Investigator; Clinical Sciences; Development; Educational Curriculum; Foundations; Generations; Health; Health Care Research; Human; Innovation Corps; Investments; Mentors; Modeling; National Center for Advancing Translational Sciences; Process; Resources; Services; Shapes; Site; Small Business Innovation Research Grant; Small Business Technology Transfer Research; Standardization; System; Technology; Testing; Trainers Training; Training; Training Programs; Translational Research; Translations; United States National Institutes of Health; biomedical scientist; clinical application; clinical center; commercialization; design; effectiveness evaluation; effectiveness validation; health care service; improved; innovation; interest; program dissemination; programs; public-private partnership; research data dissemination; translational scientist

ABSTRACT. By training our translational science workforce to better understand the commercial potential of their research, the dissemination of the I-Corps@NCATS program provides an unprecedented opportunity to accelerate scientific translation through the CTSA Hub and Network system. The I-Corps@NCATS program was initially developed with a CTSA Administrative Supplement to Enhance Network Capacity (PA-16-328). The 5-week I-Corps@NCATS short course was designed specifically to meet the needs of biomedical scientists in academic medical centers and has demonstrated significant impact on the translation of scientific discovery through commercialization. The dissemination of this program from the initial 9 I-Corps@NCATS Mentor Nodes to an additional 13 CTSA Trainee Sites will increase the innovative capacity of the CTSA Consortium and create a Translational Science National Innovation Network. We are using a robust Train-The- Trainer model that has proven effective at disseminating a standardized curriculum and approach aimed at improving our collective capacity for advancing biomedical research through to commercial products and services. This approach will expand the scope and implementation of the I-Corps@NCATS training program for clinical and translational investigators so that they may participate more fully in the commercialization process from idea generation to clinical application and be prepared as teams to compete for SBIR/STTRs and other NIH national programs. By working with 22 CTSA partners, we achieve an unparalleled critical mass of innovators, experts, resources and public-private partnerships, which can shape and coordinate healthcare research, facilitate commercialization efforts and provide a focal point for entrepreneurial interest and investment. The dissemination of the I-Corps@NCATS program will accelerate the translation of biomedical innovation across different stages of development by building the I-Corps@NCATS network capacity through a national Train-The-Trainer program (Aim 1). We will apply a set of common metrics, that have already been developed and tested, to evaluate the effectiveness and impact of the I-Corps@NCATS program across the expanded network of 22 CTSA Hubs (Aim 2). We will accelerate the transition of discoveries toward improved healthcare services by laying the foundation for further dissemination across the CTSA network and develop the Translational Science National Innovation Network (Aim 3). By disseminating an approach with demonstrated effectiveness for validating the commercial potential of innovative ideas, advancing early stage technologies and connecting potential collaborators to create new opportunities, we aim to have a significant impact on the translation of scientific discoveries to improved human health.

抽象的。通过培训我们的转化科学人员更好地了解商业潜力 他们的研究、I-Corps@NCATS 计划的传播提供了前所未有的机会 通过 CTSA 中心和网络系统加速科学转化。 I-Corps@NCATS 计划 最初是与 CTSA 行政补充文件一起开发的，以增强网络能力 (PA-16-328)。 为期 5 周的 I-Corps@NCATS 短期课程专为满足生物医学的需求而设计 学术医疗中心的科学家，并对科学成果的翻译产生了重大影响 通过商业化发现。该计划从最初的 9 个 I-Corps@NCATS 传播 另外 13 个 CTSA 实习地点的导师节点将提高 CTSA 的创新能力 联盟并创建一个转化科学国家创新网络。我们正在使用强大的Train-The- 事实证明，培训师模型可以有效地传播标准化课程和方法，旨在 提高我们推进生物医学研究直至商业产品的集体能力 服务。这种方法将扩大 I-Corps@NCATS 培训计划的范围和实施 为临床和转化研究人员提供帮助，使他们能够更充分地参与商业化 从创意产生到临床应用的过程，并为团队竞争 SBIR/STTR 做好准备 其他 NIH 国家计划。通过与 22 个 CTSA 合作伙伴合作，我们实现了无与伦比的临界质量 创新者、专家、资源和公私合作伙伴关系，可以塑造和协调医疗保健 研究、促进商业化努力并为企业家兴趣和提供焦点 投资。 I-Corps@NCATS 计划的传播将加速生物医学的转化 通过构建 I-Corps@NCATS 网络能力，实现不同发展阶段的创新 国家培训师培训计划（目标 1）。我们将应用一组通用指标，这些指标已经 开发和测试，以评估 I-Corps@NCATS 计划的有效性和影响 由 22 个 CTSA 中心组成的扩展网络（目标 2）。我们将加速发现的转变 通过为 CTSA 网络的进一步传播奠定基础，改善医疗保健服务 发展转化科学国家创新网络（目标 3）。通过传播一种方法 证明了验证创新想法的商业潜力、推进早期阶段的有效性 技术并连接潜在的合作者以创造新的机会，我们的目标是拥有重要的 对科学发现转化为改善人类健康的影响。